# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001062993-25-015668
**Filing Date:** 2025-9
**Character Count:** 4743
**Document Hash:** 39a53f64bb3050f6a9290614310020c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-015668.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0001062993-25-015668

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250903

**FILED AS OF DATE**: 20250917

**DATE AS OF CHANGE**: 20250916

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 251318580

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**<br>**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **<u>September, 2025</u>**.

Commission File Number: <u>**001-40673**</u>

<br><u>**Cybin Inc.**</u><br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

**INCORPORATION BY REFERENCE**

Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. [333-284173](http://www.sec.gov/Archives/edgar/data/1833141/000106299325000510/formf10.htm)) of the Company, as amended or supplemented.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CYBIN INC.** | **CYBIN INC.** |
|  | (Registrant) | (Registrant) |
| Date: September 17, 2025 | By: | */s/* Greg Cavers |
|  | Name: | Greg Cavers |
|  | Title: | Chief Financial Officer |

---

------

<u>**EXHIBIT INDEX**</u>

[99.1](exhibit99-1.htm) [Material Change Report dated September 3, 2025](exhibit99-1.htm)

------

## Exhibit 99.1

------

**FORM 51-102F3<br>MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Cybin Inc. (the "**Company**")

100 King Street West, Suite 5600<br>Toronto, Ontario<br>M5X 1C9

**Item 2. Date of Material Change**

September 2, 2025

**Item 3. News Release**

A news release with respect to the material change was disseminated by the Company on September 2, 2025 through Business Wire.

**Item 4. Summary of Material Change**

Effective September 2, 2025, Doug Drysdale stepped down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, was appointed as Interim Chief Executive Officer by the Board of Directors.

**Item 5. Full Description of Material Change**

Effective September 2, 2025, Doug Drysdale stepped down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, was appointed as Interim Chief Executive Officer by the Board of Directors.

Mr. So is a Co-Founder and Executive Chairman of the Company. He is a veteran owner, operator and investor in numerous companies over the last 20 years and has led corporate strategy, development, and finance at all stages of the business life cycle from start-up to growth stage and multinational.

The Board of Directors has established a committee to conduct a search for a new Chief Executive Officer. The Committee and the Board aim to move swiftly to bring onboard a new leader who will lead the Company through commercialization and ensure that the Company delivers on its commitment to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for patients.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Further information regarding the matters described in this report may be obtained from Gabriel Fahel,

------

Chief Legal Officer of the Company, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601.

**Item 9. Date of Report**

September 3, 2025.

------